BSE · 506919
Makers Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹11 Cr with net profit ₹-1 Cr — a -8.52% net margin, versus 1.65% the period before.
Shareholding
As of 2026-06-30
- Promoter61.27%
- Public38.34%
- DII0.39%
3,745 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.71× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #31 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 423.85 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,264 Cr | 326.41 | 19.62 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.51 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd. | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
| Makers Laboratories Ltd.(this company) | ₹90 Cr | 43.02 | 1.23 | 3.22% | 1.67% |
AI analysis
AI-generated · google/gemini-2.5-flashMakers Laboratories Ltd. (506919) has a market capitalization of Rs 91 Cr. The company reported a profit margin of 167.15% and has a debt-to-equity ratio of 0.12. Earnings per share stand at Rs 3.54, with a return on equity of 322.43% and a return on capital employed of 15.08%.
Positives
- +The company's profit margin is high at 167.15%.
- +Return on equity (ROE) is considerably high at 322.43%.
- +The debt-to-equity ratio is low at 0.12, indicating a healthy financial structure.
- +Promoter holding of 61.27% is substantial.
- +No shares are reported to be pledged by promoters.
Negatives
- −The annual net profit for March 2026 was negative at -Rs 0.96 Cr.
- −The annual EBITDA for March 2026 was negative at -Rs 1.04 Cr.
- −The company does not pay a dividend, with a dividend yield of 0%.
- −No revenue growth figure was provided in the data.
Financial Performance
In the quarter ending March 2026, Makers Laboratories Ltd. reported revenue of Rs 35.75 Cr, with a net profit of Rs 1.09 Cr. This follows a December 2025 quarter where revenue was Rs 35.67 Cr and net profit was Rs 0.94 Cr. For the full year ending March 2026, the company recorded revenue of Rs 11.27 Cr and a net loss of Rs 0.96 Cr.
Profitability & Returns
The company's profitability is indicated by a profit margin of 167.15%. Return on equity (ROE) is 322.43%, while return on capital employed (ROCE) is 15.08%. Earnings per share (EPS) for Makers Laboratories Ltd. are Rs 3.54.
Balance Sheet
Makers Laboratories Ltd. maintains a low debt-to-equity ratio of 0.12, indicating limited reliance on debt financing. The book value per share is Rs 123.59.
Ownership & Pledges
Public shareholding stands at 38.34%, with institutions holding 0.39%. There are no reported pledged shares by the promoters.
Regulatory & Surveillance
No information regarding regulatory scrutiny or inclusion on a surveillance list is available for Makers Laboratories Ltd. within the provided data.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.